Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab vs Dacarbazine or Temozolomide in Advanced Melanoma
NCT00257205Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2006
- Primary completion
- Aug 2010
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 21
01
Overview
A Phase 3 trial of tremelimumab in melanoma, sponsored by AstraZeneca. Started Mar 2006; status: completed.
02
Drugs
tremelimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00257205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257205.